Attending surgeon
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Italy)
Milano, Lombardia, Italy
Dario Baratti, MD has spent most of his professional life at the National Cancer Institute in Milan (Italy). His main focus of interest are the management of advanced abdominal cancers. He is an international opinion leader in the treatment of peritoneal surface malignancies by cytoreductive surgery and HIPEC. Dario Baratti, MD has a publication track record of 141 indexed papers (https://pubmed.ncbi.nlm.nih.gov) and H-index of 51 (www.Scopus.com). He has been invited as a faculty member of all the last meetings of Peritoneal Surface Oncology Group International (PSOGI): Paris, 2018 (www.psogi2018.com), Washington, DC, 2016 (www.psogi.com/meetings/10th-international-congress-on-peritoneal-surface-malignancies-2016), Amsterdam, 2014 (www.psogi.com/meetings/9th-international-congress-on-peritoneal-surface-malignancies), Berlin, 2012 (www.psogi.com/meetings).
In 2012, Dario Baratti, MD has started a program at the Surgery Department of the National Cancer Institute in Milan (Italy) to manage advanced and/or relapsed colorectal cancer by advanced cytoreductive surgical procedures. The results have been recently reported at the Society of Surgical Oncology meeting (14th International Symposium on Regional Cancer Therapies. Phoenix, AZ. February 16-18, 2019. www.surgonc.org/meetings-events/regional-cancer-therapies) and in the Annals Of Surgical Oncology (Baratti et al. Ann Surg Oncol. 2020;27:98-106)
Dario Baratti, MD is the principal investigator of two research projects currently ongoing:
- “Pilot study of feasibility and safety of Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the prevention of peritoneal metastases after curative intent-surgery for high-risk colorectal cancer” (financially supported by the Institutional Research Fund of the National Cancer Institute in Milan) ;
- “Organoids from colorectal peritoneal metastases to improve cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). A phase II trial.” (financially supported by the Italian Health Ministry – Bando per la Ricerca Finalizzata 2019).
Dario Baratti is the senior surgical member of the Institutional Review Board, and a member of the Advisory Board of the Scientific Directorate at the National Cancer Institute, Milan (Italy).
I do not have any relevant financial / non-financial relationships with any proprietary interests.
Saturday, March 12, 2022
11:31 AM – 11:39 AM CST
Saturday, March 12, 2022
11:39 AM – 11:41 AM CST